Jeevan Scientific Technology FY26: Revenue Jumps 31% to ₹61.5 Cr, Profit Limps to ₹1.15 Cr, and the Market Pays 128x for the Combination

General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.

1 — At a Glance

Jeevan Scientific Technology closed FY26 with consolidated revenue of ₹61.5 crore, up from ₹46.8 crore a year earlier — a 31% climb that is the loudest number on the page. The profit line is quieter: net profit of ₹1.15 crore, against ₹0.13 crore in FY25. The fourth quarter did most of the heavy lifting, posting ₹21.3 crore of sales and ₹4.29 crore of operating profit after a first half that ran at a loss.

Sitting beside that recovery is a market capitalisation of ₹147 crore and a P/E of 128 — a multiple that assumes a great deal about what a ₹1.15 crore profit becomes next. The equity base swelled during the year through preferential allotments, promoter holding fell from 38.05% to 30.25%, and cash flow from operations dropped to near zero even as the P&L improved.

So the year holds two stories at once: an operating business finding a second wind in the back half, and a balance sheet being reshaped by fresh capital, warrants, and an acquisition. The attention signal is the revenue jump. The worry signal is that the profit under it is small enough to fit in a rounding error. A business that raises capital faster than it earns it is telling you where the growth is expected to come from — and it isn’t operations yet.

Which half of the story is the real one? That’s the entry.

2 — Introduction

Incorporated in 1999 and listed on the BSE, Jeevan Scientific Technology is an independent clinical Contract Research Organization operating out of Hyderabad. It runs a single reportable segment — Clinical Research Services — which keeps its financial statements refreshingly free of the segment-note gymnastics larger CROs indulge in.

The recent history is one of expansion by allotment. During FY26 the company issued 40,85,000 fully paid equity shares to non-promoters, 30,00,000 convertible warrants to the promoter group, and 5,00,000 warrants to non-promoters under a preferential allotment, raising ₹3,074 lakh. It increased authorised capital, adopted a new memorandum, and pushed the equity share capital from ₹15.83 crore to ₹19.92 crore.

Alongside the fundraising, the group extended its structure. Nayas Laboratories Private Limited is now a 59.26% subsidiary, and Naya Pharma Private Limited an associate at 31.03%, with the company having approved investments, loans, and guarantees connected to Naya Pharma of up to ₹120 crore over the past two years. Management also cleared a US FDA remote regulatory assessment of its Hyderabad clinical pharmacology facility in early 2026, and completed a CDSCO inspection in June 2026 for adding beds to its bioequivalence centre.

The through-line: a small CRO that spent the year raising money and building a group around itself.

3 — Business Model: WTF Do They Even Do?

Jeevan Scientific gets paid to run the unglamorous machinery behind drug approvals. Three service lines carry the revenue. Clinical trial services cover patient PK trials, early and late-phase studies, post-marketing surveillance, and support for complex generics and biosimilars. Bioavailability and bioequivalence services handle the BA/BE studies — the “does the generic behave like the original” work — including food-effect, gender-effect, and pre/post-menopausal studies, with statistical analysis on SAS and WinNonlin. Pharmacovigilance rounds it out with data migration, literature searches, and audit support.

The physical plant is the moat, such as it is: a 20,000 sq. ft. research centre with 132 beds across four clinical pharmacology units, a bioanalytical lab with ten LC-MS/MS systems, and an NABL-accredited pathology lab. This is a business where regulators, not customers, decide whether you exist — which is why the FDA and CDSCO inspection notices are corporate events rather than footnotes. The June 2026 CDSCO inspection was specifically to add more beds, which tells you the constraint on a bed-based CRO: you can only run as many subjects as you can lie down.

Revenue historically skews domestic — roughly 74% India, 26% exports in FY24 — so this is a CRO with global accreditations earning most of its money at home. The export share has wandered between 24% and 43% over the decade, which is less a strategy than a symptom of a company small enough that a single large study moves the mix.

The model, in short: rent out beds, instruments, and regulatory credibility to pharma companies who’d rather not build their own. Capital-heavy, approval-gated, and only as scalable as the next inspection allows.

Does a 132-bed CRO with global accreditations grow into its ₹147 crore market cap, or does the bed count become the ceiling?

4 — Financials Overview

Figures are consolidated, in ₹ crore.

The fourth quarter more than doubled year-on-year revenue and swung operating profit from a ₹0.38 crore loss to a ₹4.29 crore profit. Against the immediately prior quarter, revenue ticked up while operating profit eased from ₹5.23 crore to ₹4.29 crore — the December quarter carried the higher operating margin at 27.4% versus 20.2% in March.

What the quarterly table hides is the shape of the full year: the first half of FY26 ran negative operating profit (a ₹0.38 crore loss in Q1, a ₹1.78 crore loss in Q2), and the entire annual result was manufactured in the back six months. A company whose whole profit lives in its final two quarters is a company whose annual number depends on the calendar cooperating.

5 — Market Expectations & Historical Multiples

This section describes how the market is currently pricing the company and how that compares with its own history and peer group. It is descriptive, not predictive.

The market currently pays 128x earnings here, against a peer median of about 39x. On returns, the company’s 1.89% ROE sits close to its own five-year average of 2.48%, and its 5.01% ROCE runs at roughly half the peer median of 10.04%.

What the market appears to be pricing is not the trailing profit of ₹1.15 crore — at that level the multiple is arithmetically extreme — but the trajectory: revenue up 31% in the year, a back-half operating recovery, fresh capital raised for capacity and acquisitions, and the ₹120 crore Naya Pharma structure being built out. The P/E is describing an expectation about scale, not a verdict on the current earnings base. The EV/EBITDA of 14.7 sits far below the P/E precisely because operating profit and depreciation exist in volume while bottom-line profit is thin after interest and tax.

The one factual observation about market expectations: the multiple prices a business several years ahead of the one the income statement currently shows.

6 — What’s Cooking

The FY26 event list is genuinely busy for a company this size. The preferential allotment dominates: ₹3,074 lakh raised via 40,85,000 equity shares and 35,00,000 warrants, earmarked across capex, working capital, subsidiary funding, and — the notable line — ₹1,000 lakh toward acquiring an API/formulation unit. Of that, ₹300 lakh was deployed in the quarter toward acquiring 60% of Naya Pharma.

On the regulatory front, the US FDA concluded a remote regulatory assessment of the Hyderabad clinical pharmacology facility in January 2026, and CDSCO completed a June 2026 inspection to approve additional beds at the bioequivalence centre. Separately, Padmaja Private Trust was allotted 15,00,000 shares (7.53%) via preferential route in January 2026.

None of these is a share-price event; each is a capacity or structure event. For a bed-and-instrument CRO, “we filed for more beds” and “we bought a formulation unit” are the operational headlines — real news, modest scale.

7 — Balance Sheet

Assets equal liabilities in every column, as they should.

• Net worth jumped ₹22 crore in one year — almost entirely the preferential capital, not retained earnings, since the year’s profit was ₹1.15 crore. The balance sheet grew by fundraising, not by working.
• Borrowings barely moved (₹20.58 crore to ₹21.28 crore) while the asset base expanded 36%. The new money was equity, not debt.
• Cash and bank rose from ₹0.24 crore to ₹9.51 crore — but against ₹21.28 crore of borrowings, this is a net-debt position of roughly ₹11.8 crore, not a cash pile.

A balance sheet that expands faster than its own profit is a balance sheet betting on tomorrow with today’s investors’ money.

8 — Cash Flow: Sab Number Game Hai

Follow the money and the year explains itself. Operating cash collapsed from ₹10.07 crore to ₹0.42 crore even as the P&L improved — the profit went into receivables and inventory rather than the bank. Investing stayed firmly negative at ₹9.98 crore as capex and the Naya Pharma investment went out the door. Financing carried the whole year at ₹18.83 crore, which is the preferential allotment arriving.

The tell: when operations generate ₹0.42 crore and financing generates ₹18.83 crore, the cash in the business this year came from selling shares, not selling studies.

9 — Ratios: Sexy or Stressy?

ROE at 1.89% means the equity is working roughly one day a fortnight. ROCE of 5.01% sits below what the borrowings cost to service — the interest coverage of 2.02x confirms the capital is barely out-earning its own interest bill. The PAT margin of 1.87% says that of every ₹100 of revenue, ₹1.87 survives to the bottom line, which is what happens when depreciation of ₹6.64 crore and interest of ₹2.04 crore eat an operating profit of ₹9.80 crore. Debt-to-equity of 0.30 is the one comfortable number here — modest leverage on a freshly enlarged equity base.

10 — P&L Breakdown: Show Me the Money

Operating profit has genuinely climbed — ₹4.64 crore to ₹9.80 crore over two years — and other income at ₹0.97 crore is small enough that the profit is real business, not one-off gains. That’s the honest good news. The gap between ₹9.80 crore of operating profit and ₹1.15 crore of PAT is depreciation (₹6.64 crore) and interest (₹2.04 crore), which is the structural cost of running a bed-and-instrument business on borrowed and raised capital.

An EPS guard is worth flagging: PAT rose from ₹0.13 crore to ₹1.15 crore — nearly nine-fold — but EPS rose from ₹0.08 to ₹0.58, roughly seven-fold. The gap is the share count: the count went from about 1.58 crore to 1.99 crore shares over the year via the preferential allotment and ESOP exercise. The per-share improvement is diluted by the fact that more shares now split the profit. The business did better; each share captured a little less of the better.

11 — Peer Comparison

Jeevan carries the highest multiple in the set on the smallest revenue base. Against Vimta Labs — the closest genuine comparable in the CRO space — Jeevan trades at roughly four times the multiple on a fifth of the quarterly revenue and a fraction of the 25% ROCE Vimta posts. Even Novelix Pharma, the other micro-cap here, sits at 67x against Jeevan’s 128x. The peer median P/E is about 39x; Jeevan is priced at more than three times that.

12 — Miscellaneous: Shareholding & Promoters

Promoter holding fell from 38.05% to 30.25% over the year — an 7.80% drop driven by the preferential allotment of 40,85,000 shares to non-promoters, which mechanically diluted the promoter group’s slice. There are no institutional holders of note; this is a company owned by its promoters and a wide public base of over 5,000 shareholders.

The promoter group is family-anchored — Krishna Kishore Kuchipudi is Managing Director (DIN 00876539), with K Vanaja, Jeevan Krishna Kuchipudi, and others holding the remaining promoter stake. The conduct note worth recording: the group took warrants for itself in the same allotment that diluted its equity percentage, which is a way of participating in the raise without writing the full cheque upfront. No pledging is reported — the promoter shares are clean of that particular encumbrance.

13 — Corporate Governance: Angels or Devils?

The auditor position is clean: Pavuluri & Co. issued an unmodified, unqualified opinion on both standalone and consolidated FY26 results. During the year the board appointed KP & Associates as internal auditors and granted 4,80,000 ESOP options while allotting 1,61,250 shares on exercise.

Two items belong in the record without embellishment. The annual secretarial compliance report flags a ₹2,360 fine for a Stakeholders Committee non-compliance — small in rupees, but a compliance slip is a compliance slip. And the FY25 cycle saw the COO resign. The company has reported repeated profits yet paid no dividend, and promoter holding at 30.25% is on the lower side for a promoter-run company. Pledging stands at zero, and the audit opinion carries no qualification — so the governance ledger reads as a clean audit with a couple of housekeeping marks against it, rather than a red-flag file.

14 — Industry Roast & Macro Context

The Indian CRO industry is a business of accreditations and beds, where your addressable market is decided by whichever regulator inspected you last. It’s a sector where a US FDA nod or a WHO clearance is worth more than any marketing budget, and where losing one can vaporise a client list overnight. Pricing is set by global pharma sponsors who can shop across every accredited bed in India, which keeps margins honest and small players perpetually competing on cost and turnaround.

The macro tailwind is real: complex generics, biosimilars, and the relentless need for bioequivalence data keep the study pipeline full. The macro trap is equally real — this is capital-heavy, cyclical work, and a bed sitting empty still depreciates. Scale players like Syngene run thousand-crore quarters; the micro-caps live study to study, quarter to quarter, hoping the next inspection comes back clean. It’s an industry where the barrier to entry and the ceiling on growth are the same wall: regulatory approval.

15 — EduInvesting Verdict

Jeevan Scientific spent FY26 doing two things at once: growing a real CRO 31% at the top line, and raising the capital to become something bigger than a ₹1.15 crore profit. The operating recovery is genuine; the valuation is written for the version of this company that doesn’t exist on the income statement yet.

A business that raised more capital in a year than it has earned in a decade, priced at 128x for a profit that fits in a footnote — the growth is real, the multiple is a promise, and the two haven’t met yet.